Roberto Pazo-Cid

15PUBLICATIONS
111CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gastroenterology and hepatologyCancer geneticsMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Nov 18, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.

Marcia Cruz-Correa, Do-Youn Oh, Ken Kato

|Aug 09, 2025
Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry.

Carlos López-López, Eva Martínez de Castro, Ana Fernández Montes

|Mar 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

Markus Moehler, Do-Youn Oh, Ken Kato

|Jan 25, 2025
Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management.

Carmen Blanco Abad, Paula Gomila Pons, Sara Campos Ramírez

|Nov 14, 2024
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.

Francesca Sarno, Jair Tenorio, Sofia Perea

|May 09, 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.

Susanna Hegewisch-Becker, Guillermo Mendez, Joseph Chao

Pageof 3

Frequent Collaborators

4 joint publications

Lucjan Wyrwicz

3 joint publications

Kohei Shitara

3 joint publications

Yelena Y Janjigian

3 joint publications

Markus Moehler